Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:antiSubmarineWarfare |
addressed in trials
|
| gptkbp:clinicalTrials |
yes
Phase III multiple_countries_including_Brazil_and_Turkey |
| gptkbp:community |
significant in controlling outbreaks
|
| gptkbp:communityImpact |
conducted by health authorities
|
| gptkbp:contraindication |
monitored by health authorities
mild to moderate reactions |
| gptkbp:countryOfOrigin |
gptkb:China
|
| gptkbp:date |
emergency use authorization
|
| gptkbp:developedBy |
gptkb:Sinovac_Biotech
|
| gptkbp:diseaseResistance |
varies by region
increased through campaigns logistical issues in some regions important for public trust conducted in various populations influenced by data |
| gptkbp:distribution |
global
|
| gptkbp:drugInterdiction |
2
|
| gptkbp:evaluates |
approximately 50% to 83% depending on the population
|
| gptkbp:expansion |
recommended for some populations
|
| gptkbp:hasCollaborationsWith |
essential for distribution
|
| gptkbp:hasPublications |
yes
|
| gptkbp:healthcare |
contributes to global vaccination efforts
|
| https://www.w3.org/2000/01/rdf-schema#label |
CoronaVac
|
| gptkbp:lastProduced |
gptkb:China
|
| gptkbp:marketedAs |
gptkb:CoronaVac
|
| gptkbp:notable_player |
inactivated virus technology
subunit vaccine ongoing for variants monitored post-authorization addressed by public health campaigns important for uptake ongoing for safety and efficacy ongoing in many countries part of global vaccine efforts supported by various entities with various governments and organizations |
| gptkbp:producedBy |
gptkb:Sinovac_Biotech
|
| gptkbp:providesAccessTo |
part of pandemic response strategies
|
| gptkbp:providesGuidelinesFor |
provided by health organizations
|
| gptkbp:providesSupportFor |
various_countries_including_Indonesia_and_Brazil
|
| gptkbp:regulatoryCompliance |
multiple countries
ensured by manufacturers |
| gptkbp:reproduction |
induces neutralizing antibodies
|
| gptkbp:route |
intramuscular injection
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:systemRequirements |
standard refrigeration
|
| gptkbp:takesPlaceIn |
critical for distribution
conducted in multiple phases |
| gptkbp:targets |
gptkb:COVID-19
adults and children over 3 years old |
| gptkbp:type |
inactivated virus vaccine
|
| gptkbp:yearEstablished |
2020
|